Seeking to evolve the way it educates and engages with healthcare professionals, Novartis is using digital technology to enhance the quality, transparency and reach of its interactions with the medical community.

Patient community representatives call for improved digital health literacy, standardised digital platforms, and co-creation of digital solutions.

Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.

Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.

From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.